Table 2 Demographic data, medical and oncological history of the studied cohort
From: A single centre experience of patients with rare cancers referred for early phase clinical trials
Characteristics of rare cancer patients referred to ECMT (2016–2020) | |
|---|---|
Characteristic | Numbers |
Referrals to ECMT | Total: 3118, Rare cancers: 317 (10.2%) |
Patients reviewed by ECMT | 240 patients |
Sex (patients, %) | Males: 110 (45.8%), Females: 130 (54.2%) |
Age at diagnosis | Median: 52 years |
Range: 16 – 84 years | |
Age at diagnosis (males vs females) | Median: 57 years (males), 49 years (females) |
Metastasis at diagnosis (patients, %) | • Yes: 98 (40.8%) |
• No: 142 (59.2%) | |
Metastasis at referral point (patients, %) | • Yes: 207 (86.2%) |
• No: 33 (13.8%) | |
Number of sites of metastasis (at referral point) (patients, %) | • 0: 33 (13.8%) |
• 1: 96 (40.0%) | |
• 2: 78 (32.5%) | |
• 3 + : 33 (13.7%) | |
Time to relapse from initial diagnosis | Median: 13 months, range 1 month – 41 years |
ECOG PS at first ECMT consultation (patients, %) | • 0: 43 (17.9%) |
• 1: 168 (70.0%) | |
• 2: 24 (10.0%) | |
• 3: 5 (2.1%) | |
Active comorbidities (patients, %) | • 0: 78 (32.5%) |
• 1: 78 (32.5%) | |
• 2: 56 (23.3%) | |
• ≥ 3: 28 (11.7%) | |
Family history of any malignancy (non-hereditary) (patients, %) | • Yes: 129 (53.8%) |
• No: 74 (30.8%) | |
• Unknown: 37 (15.4%) | |
Surgery (patients, %) | • Yes: 149 (62.1%) |
• No: 91 (37.9%) | |
Radiotherapy (patients, %) | • Yes: 132 (55.0%) |
• No: 108 (45.0%) | |
SACT (patients, %) | • Yes: 190 (79.2%) |
• No: 50 (20.8%) | |
Lines of SACT (patients, %) | • 0: 50 (20.8%) |
• 1: 129 (53.8%) | |
• 2: 45 (18.7%) | |
• 3: 15 (6.3%) | |
• 4: 1 (0.4%) | |
Median: 1 line | |